SWK Holdings' Q2 Net Income Dips, H1 Soars on Credit Loss Benefit

TL;DR

**SWK's H1 net income surge is a strong buy signal, driven by credit loss benefits despite a slight Q2 revenue dip.**

AI Summary

SWK Holdings Corporation reported a net income of $3.536 million for the three months ended June 30, 2025, a slight decrease from $3.680 million in the same period of 2024. For the six months ended June 30, 2025, net income significantly increased to $8.075 million, up from $4.148 million in 2024. Total revenues for the three months ended June 30, 2025, were $10.052 million, down from $10.847 million in 2024, primarily due to a decrease in finance receivable interest income from $9.986 million to $8.543 million. However, pharmaceutical development revenue increased from $804 thousand to $1.190 million in the same period. A key business change was the revaluation of finance receivables, resulting in a loss of $3.727 million for the six months ended June 30, 2025, compared to a gain of $2.495 million in 2024. The company also saw a significant decrease in the provision for credit losses, from $9.392 million in the first six months of 2024 to a benefit of $704 thousand in 2025. Strategic outlook includes continued focus on its two segments: specialty finance and pharmaceutical development, with the latter's name changing from Enteris BioPharma, Inc. to MOD3 Pharma as of March 13, 2025.

Why It Matters

SWK Holdings' mixed financial results, with a quarterly net income dip but a strong half-year gain, signal a complex investment landscape. The significant reduction in credit loss provisions and a realized gain on early payment of finance receivables are positive for investors, indicating improved asset quality and efficient portfolio management. However, the decline in finance receivable interest income and a loss on revaluation of finance receivables suggest potential headwinds in its core lending business. For employees, the stability in pharmaceutical development revenue and the rebranding of Enteris to MOD3 Pharma could indicate growth opportunities in that segment. Customers of MOD3 Pharma might see enhanced service offerings due to the collaboration with AptarGroup, Inc. The competitive context shows SWK navigating a dynamic life sciences financing market, where effective risk management and strategic partnerships are crucial for sustained performance.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant revaluation loss on finance receivables of $3.727 million for the six months ended June 30, 2025, indicating potential volatility in asset valuation. Additionally, the decrease in finance receivable interest income from $9.986 million to $8.543 million for the three months ended June 30, 2025, suggests a potential weakening in the core finance segment's revenue generation.

Analyst Insight

Investors should closely monitor SWK's finance receivables portfolio for further revaluation losses and assess the sustainability of the reduced credit loss provisions. Consider the long-term growth potential of the pharmaceutical development segment, especially with the AptarGroup collaboration, as a diversification play against potential softness in the finance segment.

Financial Highlights

debt To Equity

0.16

revenue

$21.884M

operating Margin

58.2%

total Assets

$285.697M

total Debt

$31.736M

net Income

$8.075M

eps

$0.66

gross Margin

N/A

cash Position

$8.006M

revenue Growth

-1.4%

Revenue Breakdown

Key Numbers

• $8.075M — Net Income (Six Months) (Increased from $4.148M in 2024, a 94.7% rise)
• $3.536M — Net Income (Three Months) (Decreased from $3.680M in 2024, a 3.9% drop)
• $10.052M — Total Revenues (Three Months) (Decreased from $10.847M in 2024, a 7.3% drop)
• $8.543M — Finance Receivable Interest Income (Three Months) (Decreased from $9.986M in 2024, a 14.4% drop)
• $1.190M — Pharmaceutical Development Revenue (Three Months) (Increased from $804K in 2024, a 48.0% rise)
• ($704K) — Provision (Benefit) for Credit Losses (Six Months) (Shifted from a $9.392M provision in 2024 to a benefit in 2025)
• ($3.727M) — Loss on Revaluation of Finance Receivables (Six Months) (Shifted from a $2.495M gain in 2024 to a loss in 2025)
• $49.078M — Cash Dividends Paid (Six Months) (Significant cash outflow in 2025, none in 2024)
• $8.006M — Cash and Cash Equivalents (June 30, 2025) (Increased from $5.927M at December 31, 2024)
• 12,147,391 — Common Stock Shares Outstanding (August 7, 2025) (Slightly decreased from 12,213,599 at December 31, 2024)

Key Players & Entities

• SWK Holdings Corporation (company) — Registrant of the 10-Q filing
• Enteris BioPharma, Inc. (company) — Acquired company, now rebranded as MOD3 Pharma
• MOD3 Pharma (company) — New name for Enteris BioPharma, Inc., a pharmaceutical development and manufacturing organization
• AptarGroup, Inc (company) — Collaboration partner for CDMO services
• $8.075 million (dollar_amount) — Net income for the six months ended June 30, 2025
• $3.536 million (dollar_amount) — Net income for the three months ended June 30, 2025
• $10.052 million (dollar_amount) — Total revenues for the three months ended June 30, 2025
• $3.727 million (dollar_amount) — Loss on revaluation of finance receivables for the six months ended June 30, 2025
• $704 thousand (dollar_amount) — Benefit for credit losses for the six months ended June 30, 2025
• Nasdaq Stock Market LLC (regulator) — Exchange where SWKH and SWKHL are registered

FAQ

Risk Factors

• Credit Risk of Finance Receivables [high — financial]: The company's primary business involves finance receivables, which are subject to credit risk. The allowance for credit losses was $8.826 million as of June 30, 2025, down from $11.249 million as of December 31, 2024. A significant shift occurred in the provision for credit losses, moving from a $9.392 million expense in the first six months of 2024 to a benefit of $704 thousand in the same period of 2025.
• Revaluation of Finance Receivables [medium — financial]: The company experienced a loss of $3.727 million on the revaluation of finance receivables for the six months ended June 30, 2025, a significant swing from a gain of $2.495 million in the prior year's period. This volatility impacts profitability and financial reporting.
• Dependence on Pharmaceutical Development Segment [medium — operational]: While pharmaceutical development revenue increased by 48.0% to $1.190 million for the three months ended June 30, 2025, the company's overall revenue is still heavily influenced by its finance receivable interest income. The success and growth of MOD3 Pharma (formerly Enteris BioPharma) are critical for diversification.
• Interest Rate Sensitivity [medium — market]: As a significant portion of revenue is derived from finance receivable interest income, the company is sensitive to changes in interest rates. Fluctuations in market interest rates can impact the yield on its finance receivables and overall profitability.
• Debt Obligations [medium — financial]: The company has outstanding unsecured senior notes totaling $31.736 million and a revolving credit facility balance of $294 thousand as of June 30, 2025. Managing these debt obligations and associated interest expenses is crucial for financial health.
• Assets Held for Sale [low — operational]: The company reports 'Assets held for sale' of $6.488 million and 'Liabilities held for sale' of $1.278 million as of June 30, 2025. The successful disposition of these assets and liabilities is important for streamlining operations and potentially realizing value.

Industry Context

SWK Holdings operates in two distinct segments: specialty finance and pharmaceutical development. The specialty finance sector is characterized by its reliance on interest income and careful management of credit risk. The pharmaceutical development sector, represented by MOD3 Pharma, is highly competitive and R&D intensive, with significant potential for growth but also substantial risks. The company's strategy appears to involve leveraging its financial expertise while investing in the promising, albeit volatile, biotech sector.

Regulatory Implications

As a financial services provider, SWK Holdings is subject to various financial regulations concerning lending practices, capital adequacy, and consumer protection. Changes in these regulations could impact its operations and profitability. Furthermore, its pharmaceutical segment is subject to stringent FDA regulations for drug development and approval, posing significant compliance hurdles and timelines.

What Investors Should Do

1. Monitor the performance of the pharmaceutical development segment (MOD3 Pharma) for future growth drivers and diversification benefits.
2. Analyze the trend in finance receivable interest income and the impact of interest rate changes on profitability.
3. Evaluate the company's credit risk management, particularly the effectiveness of its allowance for credit losses and the impact of revaluation adjustments.
4. Assess the company's ability to manage its debt obligations and improve its accumulated deficit position.
5. Observe the strategic implications of assets and liabilities held for sale on the company's balance sheet and future operations.

Key Dates

• 2025-03-13: Enteris BioPharma, Inc. renamed MOD3 Pharma — Indicates a strategic rebranding or restructuring within the pharmaceutical development segment, potentially signaling a new phase of growth or focus.
• 2025-06-30: End of Second Quarter — Reporting period for the unaudited condensed consolidated financial statements, providing current performance data.
• 2025-06-30: Cash and cash equivalents increased — Cash position improved to $8.006 million from $5.927 million at December 31, 2024, indicating better liquidity.
• 2025-06-30: Finance receivables decreased — Finance receivables, net of allowance, decreased to $237.604 million from $277.760 million at December 31, 2024, reflecting a reduction in the core lending portfolio.
• 2025-06-30: Provision for credit losses turned into a benefit — A significant positive shift from a $9.392 million provision in the prior year's six months to a $704 thousand benefit in 2025, boosting net income.
• 2025-06-30: Loss on revaluation of finance receivables — A $3.727 million loss in the six months ended June 30, 2025, contrasts with a $2.495 million gain in the prior year, impacting profitability.

Glossary

Finance receivables

Loans or amounts owed to the company that are expected to be paid back with interest. These are a core asset for SWK Holdings. (The primary revenue-generating asset for the company, subject to credit risk and revaluation impacts.)

Provision (benefit) for credit losses

An accounting estimate of the amount of losses expected from loans or receivables that may not be repaid. A 'benefit' means the company expects fewer losses than previously estimated or has recovered amounts previously written off. (A significant factor impacting net income; a benefit in 2025 substantially increased profitability compared to a large provision in 2024.)

Revaluation of finance receivables

The process of adjusting the carrying value of finance receivables to their current market value, which can result in gains or losses. (Caused a substantial loss of $3.727 million in the first six months of 2025, significantly affecting the company's financial results.)

Pharmaceutical development revenue

Revenue generated from the company's activities in developing pharmaceutical products, including through its subsidiary MOD3 Pharma (formerly Enteris BioPharma). (A growing segment for SWK Holdings, showing strong revenue growth and contributing to diversification.)

Assets held for sale

Assets that management has committed to selling and are actively marketed. They are typically reported at the lower of their carrying amount or fair value less costs to sell. (Represents a portion of the company's assets that are intended for divestiture, impacting the overall asset base.)

Accumulated deficit

The total cumulative net losses of a company since its inception, less any cumulative net income. It represents a negative balance in retained earnings. (SWK Holdings has a significant accumulated deficit of ($4.172 million) as of June 30, 2025, indicating historical unprofitability.)

Year-Over-Year Comparison

Compared to the prior year, SWK Holdings shows a mixed financial performance. While total revenues for the three months ended June 30, 2025, decreased by 7.3% to $10.052 million, driven by lower finance receivable interest income, net income for the six-month period significantly increased by 94.7% to $8.075 million. This surge is largely attributable to a substantial reduction in the provision for credit losses, turning from a $9.392 million expense to a $704 thousand benefit. However, a notable negative swing occurred with a $3.727 million loss on the revaluation of finance receivables, compared to a gain in the prior year, highlighting increased financial volatility.

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share SWKH The Nasdaq Stock Market

Filing Documents

• swkh-20250630.htm (10-Q) — 1361KB
• q225ex311ceocertification.htm (EX-31.1) — 9KB
• q225ex312cfocertification.htm (EX-31.2) — 9KB
• q225ex321ceocertification.htm (EX-32.1) — 5KB
• q225ex322cfocertification.htm (EX-32.2) — 5KB
• swkh-20250630_g1.jpg (GRAPHIC) — 9KB
• 0001628280-25-040420.txt ( ) — 7970KB
• swkh-20250630.xsd (EX-101.SCH) — 45KB
• swkh-20250630_cal.xml (EX-101.CAL) — 86KB
• swkh-20250630_def.xml (EX-101.DEF) — 243KB
• swkh-20250630_lab.xml (EX-101.LAB) — 603KB
• swkh-20250630_pre.xml (EX-101.PRE) — 448KB
• swkh-20250630_htm.xml (XML) — 1377KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 Unaudited Condensed Consolidated Balance Sheets—June 30, 2025 and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Income—Three and Six Months Ended June 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Stockholders' Equity—Three and Six Months Ended June 30, 2025 and 2024 3 Unaudited Condensed Consolidated Statements of Cash Flows— Six Months Ended June 30, 2025 and 2024 4 Notes to the Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4

Controls and Procedures

Controls and Procedures 34

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Unregistered Sales of Equity Securities and Use of Proceeds. 35

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 36 Item 6. Exhibits 37

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. From time to time, we may also provide oral or written forward-looking statements in other materials we release to the public. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. The forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections about our business and industry, and our beliefs and assumptions, and include, but are not limited to, statements under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations." Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "should," "will" and variations of these words and similar expressions identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are beyond our control, are difficult to predict and could cause actual results to differ materially (both favorably and unfavorably) from those expressed or forecasted in the forward-looking statements. These risks and uncertainties include, but are not limited to, those described in Item 1A, "Risk Factors," those described in Item 1A. "Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024, and elsewhere in this report. Forward-looking statements that were believed to be true at the time made may ultimately prove to be incorrect or false. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value and share data) June 30, 2025 December 31, 2024 Assets: Current assets: Cash and cash equivalents $ 8,006 $ 5,927 Interest, accounts receivable and other receivables, net 5,611 5,788 Assets held for sale, net (Note 4) 6,488 6,398 Other current assets 1,088 2,141 Total current assets 21,193 20,254 Finance receivables, net of allowance for credit losses of $ 8,826 and $ 11,249 as of June 30, 2025 and December 31, 2024, respectively 237,604 277,760 Collateral on foreign currency forward contract — 2,750 Marketable investments 603 580 Deferred tax assets, net 21,219 23,484 Warrant assets 4,612 4,366 Other non-current assets 466 3,041 Total assets $ 285,697 $ 332,235 Liabilities and Stockholders' Equity: Current liabilities: Accounts payable and accrued liabilities $ 2,101 $ 2,810 Liabilities held for sale (Note 4) 1,278 1,255 Deferred income 3,300 1,500 Total current liabilities 6,679 5,565 Unsecured senior notes, net 31,736 31,412 Revolving credit facility 294 6,233 Other non-current liabilities 519 335 Total liabilities 39,228 43,545 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding — — Common stock, $ 0.001 par value; 250,000,000 shares authorized; 12,183,906 and 12,213,599 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 12 12 Additional paid-in capital 4,418,773 4,419,991 Accumulated deficit ( 4,172,316 ) ( 4,131,313 ) Total stockholders' equity 246,469 288,690 Total liabilities and stockholders' equity $ 285,697 $ 332,235 See accompanying notes to the unaudited condensed consolidated financial statements. 1 SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share data) Three Mont

View Full Filing

View this 10-Q filing on SEC EDGAR